Uri Alka®
for urinary tract
  • Sodium bicarbonate: acts as urinary alkaliser by increasing the excretion of free bicarbonate ions in the urine, thus effectively raising the urinary pH. By maintaining an alkaline urine, the actual dissolution of uric acid stones may be accomplished. It also acts as antacid by chemically neutralizing or buffering existing quantities of stomach acid but has no direct effect in its output. This action results in increased pH value of stomach contents, thus providing relief of hyperacidity symptoms.
  • Sodium Citrate and Citric Acid: Sodium citrate is metabolized to bicarbonates, which increases urinary pH by increasing the excreting of free bicarbonate ions, without producing systemic alkalosis when administered in recommended doses. A rise in urinary pH increases the solubility of cystine in the urine and the ionization or uric acid to more soluble urate ion. By maintaining an alkaline urine, the actual dissolution of uric acid stones may be accomplished. It also reacts chemically to neutralize or buffer existing quantities of gastric hydrochloric acid but has no direct effects in its output. Sodium bicarbonate is excreted through renal and also via lung by forming CO2. Sodium citrate, citric acid and absorbed tartaric acid are excreted through urine.

Each sachet of Uri Alka® contains: 

  • Sodium bicarbonate          1.76g.
  • Citric acid anhydrous       0.72g.
  • Sodium citrate anhydrous    0.63g.
  • Tartaric acid               0.89g.

Uri Alka® is indicated for:

  • Relieving discomfort in mild UTI.
  • symptomatic relief of dysuria.
  • to enhance the action of certain antibiotics, especially some sulphonamides.
  • in gout therapy as urinary alkalinisers to preventcrystallisation of urates.

Uri Alka® is contraindicated in :

  • Renal failure or hypernatremia; in conjunction with hexamine mandelate or hexamine hippurate therapy because an acidic urine is needed.
  • Caution is advised in overt and occult cardiac failure.
  • Concomitant use of urinary alkalinisers and quinolone antibiotics  should be avoided.
  • crystalluria may be more likely to occur in alkaline urine.
  • Alkalinization of the urine due to the use of Urialka®, theoretically, may result in a decreased therapeutic effect of the following medications; chlorpropamide, lithium, salicylates and tetracyclines.
  • Alkalinization of the urine due to the use of Urialka®, theoretically, may result in an increased therapeutic effect of the following medications; amphetamines and ephadrine / pseudoepherine.
  • Antacid: Concurrent use of antacids with sodium citrate and sodium bicarbonate may promote the development of calcium stones in patients with uric acid stones and may also cause hypernatremia.
  • Concurrent use of aluminium-containing antacids with salts can increase aluminium absorption, possibly resulting in acute aluminium toxicity, especially in patients with renal insufficiency.
  • Quinolones: Citrates may reduce the solubility of ciprofloxacin, norfloxacin, or ofloxacin in the urine. Patients should be observed for signs of crystalluria and nephrotoxicity.
  • Laxatives: Concurrent administration of citrates with laxatives may have an additive effect.
  • Studies regarding the effect of citrates on pregnancy have not been done.
  • Caution should be exercised when administered to a nursing mother.
  • The tartrate component of Urialka® may be completely absorbed. Because of this Urialka® may exert a mild laxative effect.
  • Prolonged and excessive use may cause a systemic alkalosis and / or hypernatremia.


  • Overdosage may result in metabolic alkalosis Urialka® should be discontinued, appropriate treatment instituted and electrolyte and acid-base determinations should be carried out as appropriate.
  • 1 to 2 sachets dissolved in cold water four times daily or as prescribed.
  • Uri Alka® contains 644mg of sodium per sachet which should be taken into account by those on a low sodium diet.  
  • 10 sachets per pack.
  • Store in a dry place below 25°C.